fluorobenzenes has been researched along with farnesyl pyrophosphate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barth, S; Dahm, JB; Felix, SB; Jantzen, F; Könemann, S; Kroemer, HK; Landsberger, M; Staudt, A; Wolff, B | 1 |
1 other study(ies) available for fluorobenzenes and farnesyl pyrophosphate
| Article | Year |
|---|---|
Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
Topics: Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Endothelium, Vascular; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Mevalonic Acid; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Polyisoprenyl Phosphates; Pyridines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sesquiterpenes; Sulfonamides; Terpenes; Time Factors; Tumor Necrosis Factor-alpha; Umbilical Veins; Up-Regulation | 2007 |